ロード中...
Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil–based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to folfiri and f...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Multimed Inc.
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2768516/ https://ncbi.nlm.nih.gov/pubmed/19862366 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|